Spots Global Cancer Trial Database for A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Official Title: A Study on Association Between Homologous Recombination Genes and the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer

Study ID: NCT04651920

Conditions

Epithelial Ovarian Cancer

Chinese

Homologous Recombination Deficiency

BRCA1 Mutation

BRCA2 Mutation

Prognosis

Homologous Recombination Genes

Interventions

Evaluation of homologous recombination deficiency score

Study Description

Brief Summary: The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Detailed Description: